Delaware
|
|
31-1080091
|
(State or other jurisdiction of
incorporation or organization)
|
|
(IRS Employer
Identification No.)
|
5600 Blazer Parkway, Suite 200, Dublin, Ohio
|
|
43017-7550
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Large
accelerated filer
|
☐
|
Accelerated
filer
|
☒
|
Non-accelerated
filer
|
☐
|
Smaller
reporting company
|
☐
|
Emerging
Growth Company
|
☐
|
|
|
PART I – Financial Information
|
|
|
||
|
|
|
|
|
Item
1.
|
Financial
Statements
|
|
3
|
|
|
|
|
|
|
|
Consolidated
Balance Sheets as of March 31, 2017 (unaudited) and
December 31, 2016
|
|
3
|
|
|
|
|
|
|
|
Consolidated
Statements of Operations for the Three-Month Periods Ended
March 31, 2017 and 2016 (unaudited)
|
|
4
|
|
|
|
|
|
|
|
Consolidated
Statement of Stockholders’ Equity (Deficit) for the
Three-Month Period Ended March 31, 2017
(unaudited)
|
|
5
|
|
|
|
|
|
|
|
Consolidated
Statements of Cash Flows for the Three-Month Periods Ended
March 31, 2017 and 2016 (unaudited)
|
|
6
|
|
|
|
|
|
|
|
Notes
to the Consolidated Financial Statements
(unaudited)
|
|
7
|
|
|
|
|
|
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
|
20
|
|
|
|
|
|
|
|
Forward-Looking
Statements
|
|
20
|
|
|
|
|
|
|
|
The
Company
|
|
20
|
|
|
|
|
|
|
|
Product Line
Overview
|
|
21
|
|
|
|
|
|
|
|
Outlook
|
|
25
|
|
|
|
|
|
|
|
Discontinued
Operations
|
|
25
|
|
|
|
|
|
|
|
Results of
Operations
|
|
26
|
|
|
|
|
|
|
|
Liquidity and
Capital Resources
|
|
26
|
|
|
|
|
|
|
|
Recent
Accounting Standards
|
|
29
|
|
|
|
|
|
|
|
Critical
Accounting Policies
|
|
29
|
|
|
|
|
|
|
Item
3.
|
Quantitative and
Qualitative Disclosures About Market Risk
|
|
30
|
|
|
|
|
|
|
Item
4.
|
Controls and
Procedures
|
|
31
|
|
|
|
|
|
|
PART II – Other Information
|
|
33
|
||
|
|
|
|
|
Item
1.
|
Legal
Proceedings
|
|
33
|
|
|
|
|
|
|
Item
1A.
|
Risk
Factors
|
|
34
|
|
|
|
|
|
|
Item
5.
|
Other
Information
|
|
34
|
|
|
|
|
|
|
Item
6.
|
Exhibits
|
|
35
|
|
Three Months Ended
March 31,
|
|
|
2017
|
2016
|
Revenue:
|
|
|
Tc
99m tilmanocept sales revenue
|
$
—
|
$
8,800
|
Tc
99m tilmanocept license revenue
|
—
|
254,050
|
Grant
and other revenue
|
580,030
|
685,635
|
Total
revenue
|
580,030
|
948,485
|
Cost
of goods sold
|
—
|
1,489
|
Gross
profit
|
580,030
|
946,996
|
Operating
expenses:
|
|
|
Research
and development
|
705,274
|
2,072,271
|
Selling,
general and administrative
|
3,022,434
|
2,633,126
|
Total
operating expenses
|
3,727,708
|
4,705,397
|
Loss
from operations
|
(3,147,678
)
|
(3,758,401
)
|
Other
(expense) income:
|
|
|
Interest
income, net
|
24,112
|
757
|
Equity
in loss of R-NAV, LLC
|
—
|
(12,239
)
|
Change
in fair value of financial instruments
|
140,485
|
1,125,359
|
Loss
on extinguishment of debt
|
(1,314,102
)
|
—
|
Other,
net
|
(21,604
)
|
(37,292
)
|
Total
other (expense) income, net
|
(1,171,109
)
|
1,076,585
|
Loss
before income taxes
|
(4,318,787
)
|
(2,681,816
)
|
Benefit
from income taxes
|
1,454,172
|
—
|
Loss
from continuing operations
|
(2,864,615
)
|
(2,681,816
)
|
Discontinued
operations, net of tax effect:
|
|
|
Loss
from discontinued operations
|
(255,861
)
|
(1,004,433
)
|
Gain
on sale
|
88,701,501
|
—
|
Net
income (loss)
|
85,581,025
|
(3,686,249
)
|
Less
loss attributable to noncontrolling interest
|
(202
)
|
(241
)
|
Net
income (loss) attributable to common stockholders
|
$
85,581,227
|
$
(3,686,008
)
|
Income
(loss) per common share (basic):
|
|
|
Continuing
operations
|
$
(0.02
)
|
$
(0.02
)
|
Discontinued
operations
|
$
0.55
|
$
—
|
Attributable
to common stockholders
|
$
0.53
|
$
(0.02
)
|
Weighted
average shares outstanding (basic)
|
160,376,476
|
155,308,094
|
Income
(loss) per common share (diluted):
|
|
|
Continuing
operations
|
$
(0.02
)
|
$
(0.02
)
|
Discontinued
operations
|
$
0.54
|
$
—
|
Attributable
to common stockholders
|
$
0.52
|
$
(0.02
)
|
Weighted
average shares outstanding (diluted)
|
164,871,955
|
155,308,094
|
|
Preferred Stock
|
Common Stock
|
Additional
Paid-In
|
Accumulated
|
Non-controlling
|
Total
Stockholders'
|
||
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Interest
|
Equity (Deficit)
|
Balance,
January 1, 2017
|
—
|
$
—
|
155,762,729
|
$
155,763
|
$
326,564,148
|
$
(394,855,034
)
|
$
468,910
|
$
(67,666,213
)
|
Issued
stock in payment of
Board
retainers
|
—
|
—
|
16,406
|
16
|
10,484
|
—
|
—
|
10,500
|
Issued
stock in payment of
employee
bonuses
|
—
|
—
|
707,353
|
707
|
367,105
|
—
|
—
|
367,812
|
Issued
stock upon exercise of
warrants
|
—
|
—
|
5,411,850
|
5,412
|
48,707
|
—
|
—
|
54,119
|
Issued
warrants in connection
with
Asset Sale
|
—
|
—
|
—
|
—
|
3,337,187
|
—
|
—
|
3,337,187
|
Issued
warrants for extension
of
license agreement
|
—
|
—
|
—
|
—
|
333,719
|
—
|
—
|
333,719
|
Stock
compensation expense
|
—
|
—
|
—
|
—
|
147,165
|
—
|
—
|
147,165
|
Net
income
|
—
|
—
|
—
|
—
|
—
|
85,581,227
|
(202
)
|
85,581,025
|
Reclassification
of funds
invested
(see Note 8)
|
—
|
—
|
—
|
—
|
—
|
—
|
200,000
|
200,000
|
Balance,
March 31, 2017
|
—
|
$
—
|
161,898,338
|
$
161,898
|
$
330,808,515
|
$
(309,273,807
)
|
$
668,708
|
$
22,365,314
|
|
Three Months Ended
March 31,
|
|
|
2017
|
2016
|
Cash
flows from operating activities:
|
|
|
Net
income (loss)
|
$
85,581,025
|
$
(3,686,249
)
|
Adjustments
to reconcile net income (loss) to net cash provided by (used
in)
operating
activities:
|
|
|
Depreciation
and amortization
|
86,535
|
149,590
|
Loss
on disposal and abandonment of assets
|
100,270
|
—
|
Amortization
of debt discount and issuance costs
|
—
|
72,875
|
Compounded
interest on long term debt
|
143,114
|
824,952
|
Stock
compensation expense
|
147,165
|
340,502
|
Equity
in loss of R-NAV, LLC
|
—
|
12,239
|
Change
in fair value of financial instruments
|
(140,485
)
|
(1,125,359
)
|
Issued
warrants in connection with Asset Sale
|
3,337,187
|
—
|
Value
of stock issued to directors
|
10,500
|
20,640
|
Value
of stock issued to employees
|
367,812
|
—
|
Other
|
65
|
(12,239
)
|
Changes
in operating assets and liabilities:
|
|
|
Accounts
and other receivables
|
(14,821,403
)
|
903,147
|
Inventory
|
1,470,078
|
(246,030
)
|
Prepaid
expenses and other assets
|
(65,632
)
|
193,795
|
Accounts
payable
|
(3,837,463
)
|
1,133,840
|
Accrued
and other liabilities
|
(3,719,024
)
|
4,418
|
Deferred
revenue
|
(2,315,037
)
|
(265,758
)
|
Net
cash provided by (used in) operating activities
|
66,344,707
|
(1,679,637
)
|
Cash
flows from investing activities:
|
|
|
Purchases
of equipment
|
—
|
(1,847
)
|
Net
cash used in investing activities
|
—
|
(1,847
)
|
Cash
flows from financing activities:
|
|
|
Proceeds
from issuance of common stock
|
54,119
|
—
|
Principal
payments on notes payable
|
(59,498,721
)
|
—
|
Restricted
cash held for payment against debt
|
5,001,188
|
—
|
Payments
under capital leases
|
—
|
(693
)
|
Net
cash used in financing activities
|
(54,443,414
)
|
(693
)
|
Net
increase (decrease) in cash
|
11,901,293
|
(1,682,177
)
|
Cash,
beginning of period
|
1,539,325
|
7,166,260
|
Cash,
end of period
|
$
13,440,618
|
$
5,484,083
|
|
March 31,
2017
|
December 31, 2016
|
Accounts
and other receivables
|
$
—
|
$
1,598,994
|
Inventory,
net
|
—
|
1,374,618
|
Prepaid
expenses
|
—
|
170,635
|
Assets
associated with discontinued operations, current
|
—
|
3,144,247
|
Property
and equipment, net of accumulated depreciation
|
—
|
70,973
|
Patents
and trademarks, net of accumulated amortization
|
—
|
34,282
|
Assets
associated with discontinued operations, noncurrent
|
—
|
105,255
|
Total
assets associated with discontinued operations
|
$
—
|
$
3,249,502
|
|
|
|
Accounts
payable
|
$
152,108
|
$
1,957,938
|
Accrued
liabilities
|
3,402,212
|
607,659
|
Deferred
revenue
|
—
|
2,300,000
|
Liabilities
associated with discontinued operations, current
|
$
3,554,320
|
$
4,865,597
|
Liabilities Measured at Fair Value on a Recurring Basis as of March
31, 2017
|
||||
Description
|
Quoted
Prices in
Active Markets
for Identical Liabilities
(Level 1)
|
Significant
Other
Observable
Inputs (Level 2)
|
Significant
Unobservable
Inputs (Level 3)
|
Total
|
Platinum
notes payable
|
$
—
|
$
—
|
$
1,926,218
|
$
1,926,218
|
Liability
related to MT warrants
|
—
|
—
|
63,000
|
63,000
|
Liabilities Measured at Fair Value on a Recurring Basis as of
December 31, 2016
|
||||
Description
|
Quoted Prices in
Active Markets for Identical
Liabilities
(Level 1)
|
Significant
Other
Observable
Inputs (Level 2)
|
Significant
Unobservable
Inputs (Level 3)
|
Total
|
Platinum
notes payable
|
$
—
|
$
—
|
$
9,641,179
|
$
9,641,179
|
Liability
related to MT warrants
|
—
|
—
|
63,000
|
63,000
|
|
March 31,
2017
|
December 31, 2016
|
Estimated
volatility
|
110
%
|
76
%
|
Expected
term (in years)
|
0.43
|
4.75
|
Debt
rate
|
8.125
%
|
8.125
%
|
Beginning
stock price
|
$
0.58
|
$
0.64
|
|
Three Months Ended March 31, 2017
|
|||
|
Number of
Options
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life
|
Aggregate
Intrinsic
Value
|
Outstanding
at beginning of period
|
3,380,615
|
$
2.00
|
|
|
Granted
|
—
|
—
|
|
|
Exercised
|
—
|
—
|
|
|
Canceled
and Forfeited
|
(108,150
)
|
1.48
|
|
|
Expired
|
—
|
—
|
|
|
Outstanding
at end of period
|
3,272,465
|
$
2.01
|
6.2
years
|
$
10,922
|
Exercisable
at end of period
|
3,002,405
|
$
2.04
|
6.1
years
|
$
10,922
|
|
Three Months Ended
March 31, 2017
|
|
|
Number of
Shares
|
Weighted
Average
Grant-Date
Fair Value
|
Unvested
at beginning of period
|
207,000
|
$
1.17
|
Granted
|
—
|
—
|
Vested
|
—
|
—
|
Forfeited
|
—
|
—
|
Unvested
at end of period
|
207,000
|
$
1.17
|
|
Three Months Ended
March 31,
|
|
|
2017
|
2016
|
Weighted
average shares outstanding, basic
|
160,376,476
|
155,308,094
|
Dilutive
shares related to warrants
|
4,288,479
|
—
|
Unvested
restricted stock
|
207,000
|
—
|
Weighted
average shares outstanding, diluted
|
164,871,955
|
155,308,094
|
|
December 31,
2016
|
|
|
(unaudited)
|
|
Materials
|
$
—
|
$
94,500
|
Work-in-process
|
—
|
1,708
|
Finished
goods
|
748
|
—
|
Reserves
|
—
|
—
|
Total
|
$
748
|
$
96,208
|
Three Months Ended March 31, 2017
|
Diagnostics
|
Therapeutics
|
Corporate
|
Total
|
Tc
99m tilmanocept sales revenue:
|
|
|
|
|
United
States
|
$
—
|
$
—
|
$
—
|
$
—
|
International
|
—
|
—
|
—
|
—
|
Tc
99m tilmanocept license revenue
|
—
|
—
|
—
|
—
|
Grant
and other revenue
|
571,362
|
8,668
|
—
|
580,030
|
Total
revenue
|
571,362
|
8,668
|
—
|
580,030
|
Cost
of goods sold, excluding depreciation and amortization
|
—
|
—
|
—
|
—
|
Research
and development expenses,
excluding
depreciation and amortization
|
413,202
|
292,072
|
—
|
705,274
|
Selling,
general and administrative expenses,
excluding depreciation and
amortization
(1)
|
—
|
2,521
|
2,943,123
|
2,945,644
|
Depreciation and amortization
(2)
|
—
|
—
|
76,790
|
76,790
|
Income (loss) from operations
(3)
|
158,160
|
(285,925
)
|
(3,019,913
)
|
(3,147,678
)
|
Other
expense
|
—
|
—
|
(1,171,109
)
|
(1,171,109
)
|
Income
tax (expense) benefit
|
(53,254
)
|
96,273
|
1,411,153
|
1,454,172
|
Net
income (loss) from continuing operations
|
104,906
|
(189,652
)
|
(2,779,869
)
|
(2,864,615
)
|
Loss
from discontinued operations, net of tax
|
(255,861
)
|
—
|
—
|
(255,861
)
|
Gain
on sale of discontinued operations, net of tax
|
88,701,501
|
—
|
—
|
88,701,501
|
Net
income (loss)
|
88,550,546
|
(189,652
)
|
(2,779,869
)
|
85,581,025
|
Total
assets, net of depreciation and amortization:
|
|
|
|
|
United
States
|
9,692,007
|
897
|
23,116,511
|
32,809,415
|
International
|
115,279
|
—
|
893
|
116,172
|
Capital
expenditures
|
—
|
—
|
—
|
—
|
Three Months Ended March 31, 2016
|
Diagnostics
|
Therapeutics
|
Corporate
|
Total
|
Tc
99m tilmanocept sales revenue:
|
|
|
|
|
United
States
|
$
—
|
$
—
|
$
—
|
$
—
|
International
|
8,800
|
—
|
—
|
8,800
|
Tc
99m tilmanocept license revenue
|
254,050
|
—
|
—
|
254,050
|
Grant
and other revenue
|
685,635
|
—
|
—
|
685,635
|
Total
revenue
|
948,485
|
—
|
—
|
948,485
|
Cost
of goods sold, excluding depreciation and amortization
|
1,489
|
—
|
—
|
1,489
|
Research
and development expenses,
excluding
depreciation and amortization
|
1,830,471
|
241,800
|
—
|
2,072,271
|
Selling,
general and administrative expenses,
excluding depreciation and
amortization
(1)
|
—
|
(598
)
|
2,558,758
|
2,558,160
|
Depreciation and amortization
(2)
|
—
|
—
|
74,966
|
74,966
|
Loss from operations
(3)
|
(883,475
)
|
(241,202
)
|
(2,633,724
)
|
(3,758,401
)
|
Other
income (expense), excluding
equity in loss of R-NAV,
LLC
(4)
|
—
|
—
|
1,088,824
|
1,088,824
|
Equity
in loss of R-NAV, LLC
|
—
|
—
|
(12,239
)
|
(12,239
)
|
Net
income (loss) from continuing operations
|
(883,475
)
|
(241,202
)
|
(1,557,139
)
|
(2,681,816
)
|
Loss
from discontinued operations, net of tax
|
(1,004,433
)
|
—
|
—
|
(1,004,433
)
|
Net
loss
|
(1,887,908
)
|
(241,202
)
|
(1,557,139
)
|
(3,686,249
)
|
Total
assets, net of depreciation and amortization:
|
|
|
|
|
United
States
|
4,273,762
|
16,515
|
7,610,817
|
11,901,094
|
International
|
380,982
|
—
|
1,605
|
382,587
|
Capital
expenditures
|
—
|
—
|
1,847
|
1,847
|
|
Three Months Ended
March 31,
|
|
Development Program
(a)
|
2017
|
2016
|
Lymphoseek
|
$
241,687
|
$
585,195
|
Manocept
Platform
|
318,688
|
153,841
|
Macrophage
Therapeutics
|
252,073
|
187,583
|
NAV4694
(b)
|
(553,743
)
|
564,558
|
NAV5001
|
—
|
54,424
|
10.1
|
|
Global
Settlement Agreement dated March 3, 2017 by and among Navidea
Biopharmaceuticals, Inc., Cardinal Health 414, LLC, Macrophage
Therapeutics, Inc., Capital Royalty Partners II L.P., Capital
Royalty Partners II (Cayman), L.P., Capital Royalty Partners II
– Parallel Fund “A” L.P., Parallel Investment
Opportunities Partners II L.P. and Capital Royalty Partners II
– Parallel Fund “B” (Cayman) L.P. (incorporated
by reference to Exhibit 10.1 to the Company’s Current Report
on Form 8-K filed March 8, 2017).
|
|
|
|
10.2
|
|
License-Back
Agreement, dated March 3, 2017, between Navidea Biopharmaceuticals,
Inc. and Cardinal Health 414, LLC (incorporated by reference to
Exhibit 10.3 to the Company’s Current Report on Form 8-K
filed March 8, 2017).
|
|
|
|
10.3
|
|
Warrant,
dated March 3, 2017, issued to Cardinal Health 414, LLC
(incorporated by reference to Exhibit 10.4 to the Company’s
Current Report on Form 8-K filed March 8, 2017).
|
|
|
|
10.4
|
|
Warrant,
dated March 3, 2017, issued to The Regents of the University of
California (San Diego) (incorporated by reference to Exhibit 10.5
to the Company’s Current Report on Form 8-K filed March 8,
2017).
|
|
|
|
10.5
|
|
Amended
and Restated License Agreement, dated March 3, 2017, between
Navidea Biopharmaceuticals, Inc. and The Regents of the University
of California (San Diego) (portions of this Exhibit have been
omitted pursuant to a request for confidential treatment and have
been filed separately with the Securities and Exchange Commission)
(incorporated by reference to Exhibit 10.6 to the Company’s
Current Report on Form 8-K filed March 8, 2017).
|
|
|
|
10.6
|
|
Employment Agreement dated May 4, 2017,
by and between Navidea Biopharmaceuticals, Inc. and Jed A.
Latkin.*
|
|
|
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002.*
|
|
|
|
31.2
|
|
Certification of
Chief
Operating Officer and Chief Financial Officer pursuant to Section
302 of the Sarbanes-Oxley Act of 2002.*
|
|
|
|
32.1
|
|
Certification of Chief Executive Officer of Periodic Financial
Reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
18 U.S.C. Section 1350.**
|
|
|
|
32.2
|
|
Certification of
Chief
Operating Officer and Chief Financial Officer of Periodic Financial
Reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
18 U.S.C. Section 1350.**
|
|
|
|
101.INS
|
|
XBRL Instance Document*
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document*
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document*
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document*
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document*
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase
Document*
|
|
NAVIDEA
BIOPHARMACEUTICALS, INC.
|
|
|
|
(the
Company)
|
|
|
|
May 10,
2017
|
|
|
|
|
|
|
|
By:
|
/s/ Jed
A. Latkin
|
|
|
|
|
|
|
Jed A.
Latkin
|
|
|
|
Chief Operating Officer and Chief Financial
Officer
|
|
|
|
(authorized
officer; financial and accounting officer)
|
|
10.1
|
|
Global
Settlement Agreement dated March 3, 2017 by and among Navidea
Biopharmaceuticals, Inc., Cardinal Health 414, LLC, Macrophage
Therapeutics, Inc., Capital Royalty Partners II L.P., Capital
Royalty Partners II (Cayman), L.P., Capital Royalty Partners II
– Parallel Fund “A” L.P., Parallel Investment
Opportunities Partners II L.P. and Capital Royalty Partners II
– Parallel Fund “B” (Cayman) L.P. (incorporated
by reference to Exhibit 10.1 to the Company’s Current Report
on Form 8-K filed March 8, 2017).
|
|
|
|
10.2
|
|
License-Back
Agreement, dated March 3, 2017, between Navidea Biopharmaceuticals,
Inc. and Cardinal Health 414, LLC (incorporated by reference to
Exhibit 10.3 to the Company’s Current Report on Form 8-K
filed March 8, 2017).
|
|
|
|
10.3
|
|
Warrant,
dated March 3, 2017, issued to Cardinal Health 414, LLC
(incorporated by reference to Exhibit 10.4 to the Company’s
Current Report on Form 8-K filed March 8, 2017).
|
|
|
|
10.4
|
|
Warrant,
dated March 3, 2017, issued to The Regents of the University of
California (San Diego) (incorporated by reference to Exhibit 10.5
to the Company’s Current Report on Form 8-K filed March 8,
2017).
|
|
|
|
10.5
|
|
Amended
and Restated License Agreement, dated March 3, 2017, between
Navidea Biopharmaceuticals, Inc. and The Regents of the University
of California (San Diego) (portions of this Exhibit have been
omitted pursuant to a request for confidential treatment and have
been filed separately with the Securities and Exchange Commission)
(incorporated by reference to Exhibit 10.6 to the Company’s
Current Report on Form 8-K filed March 8, 2017).
|
|
|
|
10.6
|
|
Employment Agreement dated May 4, 2017,
by and between Navidea Biopharmaceuticals, Inc. and Jed A.
Latkin.*
|
|
|
|
31.1
|
|
Certification
of Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.*
|
|
|
|
31.2
|
|
Certification
of Chief Operating Officer and Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.*
|
|
|
|
32.1
|
|
Certification
of Chief Executive Officer of Periodic Financial Reports pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section
1350.**
|
|
|
|
32.2
|
|
Certification
of Chief Operating Officer and Chief Financial Officer of Periodic
Financial Reports pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, 18 U.S.C. Section 1350.**
|
|
|
|
101.INS
|
|
XBRL
Instance Document*
|
|
|
|
101.SCH
|
|
XBRL
Taxonomy Extension Schema Document*
|
|
|
|
101.CAL
|
|
XBRL
Taxonomy Extension Calculation Linkbase Document*
|
|
|
|
101.DEF
|
|
XBRL
Taxonomy Extension Definition Linkbase Document*
|
|
|
|
101.LAB
|
|
XBRL
Taxonomy Extension Label Linkbase Document*
|
|
|
|
101.PRE
|
|
XBRL
Taxonomy Extension Presentation Linkbase Document*
|
NAVIDEA BIOPHARMACEUTICALS, INC.
|
|
EXECUTIVE:
|
|
|
|
|
|
By:
|
/s/
Michael M. Goldberg
|
|
/s/ Jed
A. Latkin
|
Name:
|
Michael
M. Goldberg
|
|
Jed A.
Latkin
|
Its:
|
CEO
|
|
|
May 10, 2017
|
|
/s/ Michael M. Goldberg
|
|
|
Michael M. Goldberg, M.D.
|
|
|
President and Chief Executive Officer
|
|
|
(principal executive officer)
|
May 10, 2017
|
|
/s/ Jed A. Latkin
|
|
|
Jed A. Latkin
|
|
|
C
hief
Operating Officer and Chief Financial
Officer
|
|
|
(principal financial and accounting officer)
|
May 10, 2017
|
|
/s/ Michael M. Goldberg
|
|
|
Michael M. Goldberg, M.D.
|
|
|
President and Chief Executive Officer
|
|
|
(principal executive officer)
|
May 10, 2017
|
|
/s/ Jed A. Latkin
|
|
|
Jed A. Latkin
|
|
|
Chief Operating Officer and
Chief Financial Officer
|
|
|
(principal financial and accounting officer)
|